Remdesivir is not in the Malaysian treatment protocol for Covid-19, says Dr Adham Baba.
Tag: compulsory licensing
Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.
Only over 50,000 high-risk people were screened this year, out of an estimated 500,000 Malaysians living with Hepatitis C.
A US think tank warns Malaysia about compulsory licensing of Hepatitis C medicine, sofosbuvir, becoming a trade issue.